MAP1LC3B and colorectal carcinoma: Wang et al., Shim et al., Choi et al., and Park et al. showed 86.5% (173/200), 46.5% (47/101), 74.7% (186/249), and 79% (119/151), respectively of LC3β expression in colorectal carcinomas (21, 27–29).